Rocket Lab Caught Between UBS's Billion-Dollar Space Vision and a $3.6 Billion Financing Reality

Rocket Lab named a key beneficiary of UBS's $1.3 trillion space economy forecast, yet shares tumble 36% on analyst downgrade, $3.6B Iridium financing fears, and insider selling.

The space economy could be worth $1.3 trillion by 2040, according to a new UBS study that names Rocket Lab as one of three key beneficiaries alongside SpaceX and AST SpaceMobile. Yet the same company's stock is nursing a 36% monthly loss, caught in a vortex of analyst skepticism, acquisition financing fears, and a broader rotation out of risk assets.

UBS projects the global space market will expand at a compound annual growth rate of roughly 7%, driven by falling launch costs, expanding satellite services, and rising defense expenditure — particularly in the US and Europe. An optimistic scenario pegs the addressable market at nearly $2 trillion, though UBS trimmed that by a third to account for delays and technical hurdles. For context, the Satellite Industry Association put the narrower space market at $429 billion in 2025, with commercial satellite activities accounting for $303 billion, or 71% of the total. Ground equipment led at $165.2 billion, followed by satellite services at $105 billion.

The irony of UBS’s long-range optimism colliding with Rocket Lab’s near-term travails is not lost on traders. The stock closed Friday at €59.30, up 0.68% on the day but down 16.48% for the week and more than 36% over the past 30 days. From its 52-week high of €133.80 set in late May, the shares have shed 55.68%.

The latest leg of the sell-off was triggered by Piper Sandler analyst Alexander Potter, who initiated coverage of Rocket Lab with a neutral rating and a $83 price target. Potter praised CEO Peter Beck for building a credible alternative to SpaceX but argued that optimism over the business is already baked into the stock. On the day of the initiation, Rocket Lab shares plunged 11.7%. Potter’s call also highlighted a valuation premium to SpaceX that he expects to persist, contrasting sharply with his $100 target on AST SpaceMobile — implying upside of roughly 51%.

But the deeper source of anxiety is the planned $8 billion acquisition of Iridium Communications. To finance the deal, Rocket Lab needs a $3.6 billion bridge loan, and investors are fixated on the dilutive impact that such a large financing could have on existing shareholders. In an already jittery market, the mere prospect of dilution has amplified selling pressure.

Adding to the noise, the Equatorial Trust — a family trust linked to CEO Peter Beck — sold 3,275,779 shares between July 6 and 8 at prices ranging from roughly $81 to $102. The transactions were executed automatically through a Rule 10b5-1 trading plan established with Goldman Sachs on March 27, 2026, well before the current turmoil. Such plans are designed to insulate insiders from accusations of trading on material non-public information and say little about management’s current view of the stock. Still, in a high-valuation name under fire, the sheer volume — the plan allows up to 5 million shares, just over 10% of Beck’s direct and indirect holdings — has weighed on sentiment.

Rocket Lab is not suffering alone. A broad rotation out of risky assets is punishing the entire space sector, as investors reassess lofty valuations and the enormous capital needs of the industry. Planet Labs, for example, lost roughly 45% after a $1.5 billion capital raise sparked similar dilution fears.

Operationally, Rocket Lab’s story remains constructive. The company recently passed the System Requirements Review for the Space Development Agency’s Tracking Layer Tranche 3 constellation, a contract worth roughly $816 million. Combined with an earlier Transport Layer Beta award of around $515 million, Rocket Lab’s SDA-related backlog now exceeds $1.3 billion.

Chart readers note that the 14-day relative strength index stands at 30.2 — deep in oversold territory. The stock is trading 36.67% below its 50-day moving average of €93.64 and 11.93% below its 200-day average of €67.33, a level that previously served as support. Annualized 30-day volatility of 96.04% suggests the wild swings are far from over.

Wall Street analysts remain far more optimistic than the price action implies. Of 16 analysts covering Rocket Lab, 81% rate it a Buy or Strong Buy, with none recommending a sale. The average price target of $117 stands more than double the current level, a chasm that underscores how deeply sentiment has been punctured by the Iridium financing and Piper Sandler’s neutral call. The next catalysts come on July 22, when Iridium reports second-quarter results — albeit without the customary conference call due to the pending acquisition — and any further details on the financing structure could determine whether the stock finds a floor or extends its slide.